Irreversible electroporation for the treatment of pancreatic neuroendocrine tumors.
10.14701/kjhbps.2016.20.3.116
- Author:
Michail PAPAMICHAIL
1
;
Amir ALI
;
Michail PIZANIAS
;
Praveen PEDDU
;
John KARANI
;
Nigel HEATON
Author Information
1. Institute of Liver Studies, Kings Health Partners at King's College Hospital NHS Trust, London, United Kingdom. nigel.heaton@nhs.net
- Publication Type:Original Article
- Keywords:
Irreversible electroporation (IRE);
Pancreatic neuroendocrine tumors;
Non-thermal ablation
- MeSH:
Adenocarcinoma;
Bile;
Blood Vessels;
Electroporation*;
Follow-Up Studies;
Humans;
Length of Stay;
Methods;
Neuroendocrine Tumors*;
Pancreas;
Pancreatic Ducts;
Pancreatitis
- From:Korean Journal of Hepato-Biliary-Pancreatic Surgery
2016;20(3):116-120
- CountryRepublic of Korea
- Language:English
-
Abstract:
BACKGROUNDS/AIMS: Resection or enucleation is currently the treatment of choice for small pancreatic neuroendocrine tumors (NETs). Irreversible electroporation is a novel ablative method that is used for locally advanced pancreatic adenocarcinoma, but little data exists for its use for pancreatic NETs. We report an early experience of IRE for early pancreatic NETs. METHODS: Between April 2014 and March 2015, 3 patients with small (<2 cm) pancreatic NETs were treated with percutaneous IRE. RESULTS: There were no adverse effects during the procedure. Mean hospital stay was 2.6 days. All patients remained disease free on 12-19 months follow up. One patient developed recurrent pancreatitis with pseudocyst formation. CONCLUSIONS: IRE for small tumors of the pancreas is practical and may offer advantages over other thermal ablative techniques, since it preserves vital structures such as blood vessels, bile and pancreatic ducts. Further data regarding the long term disease free interval is required to establish efficacy.
